Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

NCT03737110 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals (UK), Ltd. as lead sponsor.

NCT NCT03737110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03737110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis
Lead sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 7, 2019
Completion date
June 30, 2022
Enrollment
86 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent pericarditis